Treatment of cognitive impairment with PDE4 inhibitor
View Patent ↗This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.
1. A method of treating mild cognitive impairment in a human in need of such treatment, the method comprising:
administering to the human suffering from mild cognitive impairment a phosphodiesterase 4 inhibitor selected from the group consisting of roflumilast, a pharmaceutically acceptable salt of roflumilast, roflumilast-N-oxide and a pharmaceutically acceptable salt of roflumilast-N-oxide,
wherein the phosphodiesterase 4 inhibitor is administered to the human at a daily dose consisting of between 50 mcg and 100 mcg.
2. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is selected from the group consisting of roflumilast and a pharmaceutically acceptable salt of roflumilast.
3. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is selected from the group consisting of roflumilast-N-oxide and a pharmaceutically acceptable salt of roflumilast-N-oxide.
4. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast.
5. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast-N-oxide.
6. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is administered at a daily dose of 50 mcg or 100 mcg.
7. The method of claim 1 , wherein the phosphodiesterase 4 inhibitor is roflumilast and wherein the phosphodiesterase 4 inhibitor is administered at a daily dose of between 50 mcg and 100 mcg.